High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy.

1 total trials

Filter these 1 trials by phase, country, sponsor and more.

Open in Search →

Showing 1–1 of 1 trials